- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.01. | Reneo Pharmaceuticals-Aktie fällt auf 52-Wochen-Tief von 7,64 US-Dollar | 3 | Investing.com Deutsch | ||
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.12.24 | Reneo Pharmaceuticals-Aktie erreicht 52-Wochen-Tief bei 7,91 US-Dollar | - | Investing.com Deutsch | ||
| 10.12.24 | OnKure reports positive early trial data for cancer drug OKI-219 | 1 | Investing.com | ||
| 10.12.24 | OnKure meldet positive frühe Studiendaten für Krebsmedikament OKI-219 | 3 | Investing.com Deutsch | ||
| 10.12.24 | OnKure Therapeutics, Inc.: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 | 81 | GlobeNewswire (Europe) | -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated... ► Artikel lesen | |
| 10.12.24 | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.12.24 | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 25.11.24 | OnKure Therapeutics, Inc.: OnKure Announces New Date for Upcoming Investor Call | 3 | GlobeNewswire (USA) | ||
| 07.11.24 | OnKure Therapeutics announces accounting firm change | 5 | Investing.com | ||
| 07.11.24 | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11.24 | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 01.11.24 | OnKure Therapeutics, Inc.: OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium | 2 | GlobeNewswire (USA) | ||
| 25.10.24 | vTv Therapeutics ends key license agreement with OnKure | 2 | Investing.com | ||
| 23.10.24 | OnKure files to sell 2.94M shares of Class A Common Stock for holders | 4 | Seeking Alpha | ||
| 10.10.24 | Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm | 1 | Benzinga.com | ||
| 10.10.24 | OnKure started at outperform by Oppenheimer, OKI-219 potential cited | 3 | Seeking Alpha | ||
| 10.10.24 | OnKure shares initiated with Outperform rating on drug potential | 3 | Investing.com | ||
| 08.10.24 | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10.24 | OnKure and Reneo Pharmaceuticals complete merger | 2 | Pharmaceutical Technology | ||
| 04.10.24 | OnKure Therapeutics, Inc. Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million | 200 | GlobeNewswire (Europe) | -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Ka), initially in breast cancer -- On track to announce early clinical... ► Artikel lesen |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 25,150 | +0,02 % | Bayer, Vidac Pharma, Pfizer - Demenz, Krebs, Fettleibigkeit: Die Jagd nach den Milliardenmärkten | Die Pharmabranche steckt mitten in einem Umbruch - hier geht es längst nicht mehr nur um Forschung, sondern um das große Geld. Wer jetzt die Nase vorn hat, sichert sich nicht nur Ruhm, sondern vor allem... ► Artikel lesen | |
| SANOFI | 103,78 | -0,40 % | Dupixent von Regeneron und Sanofi erhält bevorzuge US-Prüfung | DJ Dupixent von Regeneron und Sanofi erhält bevorzuge US-Prüfung
Von Colin Kellaher
DOW JONES--Der Entzündungshemmer Dupixent von Sanofi und Regeneron Pharmaceuticals könnte bald in einer neuen... ► Artikel lesen | |
| INNOCAN PHARMA | 0,151 | +0,67 % | Innocan Pharma erhält für seine liposomale CBD-Injektion das erste Patent in Indien | Innovative Therapie bei chronischen Schmerzen erhält Schutz des geistigen Eigentums auf Indiens 55-Milliarden-Dollar-schwerem
Pharmamarkt
Herzliya, Israel und Calgary, Alberta -... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 12,250 | +2,94 % | Assembly Biosciences, Inc.: Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes | - ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,914 | +2,35 % | Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin Sells 23,774 Shares | ||
| JAGUAR HEALTH | 0,855 | -2,98 % | Jaguar Health, Inc.: Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure | This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications... ► Artikel lesen | |
| ROYALTY PHARMA | 31,900 | -0,16 % | Dividendenbekanntmachungen (21.02.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN AUSTRALIA EQUITY FUND INC US0030111035 0,12 USD 0,1143 EUR ABRDN JAPAN EQUITY FUND INC US00306J1097 0,11 USD 0,1047 EUR ANGEL... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 35,200 | -0,06 % | BridgeBio-Aktie beschert NBC-Anlegern satte Profite | Und wieder gibt es Grund zum Feiern für die Mitglieder des Anlegerclubs No Brainer Club. Diesmal ist es die Aktie des US-Unternehmens BridgeBio Pharma, die ihnen stolze Profite von bislang mindestens... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 7,950 | +1,27 % | Corbus Pharmaceuticals CEO Yuval Cohen verkauft Aktien im Wert von 62.464 US-Dollar | ||
| SOLIGENIX | 2,440 | 0,00 % | SOLIGENIX, INC.: Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma | FLASH2 Study opens patient enrollment PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company... ► Artikel lesen | |
| KALA BIO | 6,565 | +3,06 % | KALA BIO, Inc.: KALA BIO Announces Chief Executive Officer Transition | ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 2,209 | 0,00 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the "Company" or "Aclaris"), a clinical-stage biopharmaceutical company focused on developing novel drug candidates... ► Artikel lesen | |
| NEUROGENE | 16,100 | +1,26 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 20.11.2024 | The following instruments on XETRA do have their first trading 20.11.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.11.2024
Aktien
1 PLRNBWT00031 Rainbow Tours S.A.
2... ► Artikel lesen | |
| ESSA PHARMA | 1,720 | -1,71 % | ESSA Pharma Inc: ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024 | Company continues to explore and review strategic options focused on maximizing shareholder value
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb.... ► Artikel lesen | |
| LYRA THERAPEUTICS | 0,206 | +4,10 % | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension... ► Artikel lesen |
Das Unternehmen ONKURE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 5,190 Euro und damit -4,95 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.
